Key facts
- Notable investors include Tailong VC, Hangzhou Hi-Tech Financial Investment Group, Asieris Pharmaceuticals, Hangzhou Qianhe Private Equity Fund Management, Hangzhou Tigermed Consulting Company.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Hangzhou Bailit Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Hangzhou Bailit Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hangzhou Bailit Biopharmaceuticals
Developer of biopharmaceutical products designed to advance treatments and improve patient health outcomes. The company offers innovative drug formulations, stringent quality control, scalable manufacturing processes, and compliance with regulatory standards, thereby enabling healthcare providers and pharmaceutical companies to access effective medications that support disease management and patient care.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Hangzhou Bailit Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hangzhou Bailit Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hangzhou Bailit Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.